candesartan has been researched along with catechin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Ahmed, HI; Mohamed, EA | 1 |
2 other study(ies) available for candesartan and catechin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Candesartan and epigallocatechin-3-gallate ameliorate gentamicin-induced renal damage in rats through p38-MAPK and NF-κB pathways.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Caspase 3; Catechin; Drug Therapy, Combination; Gene Expression Regulation; Gentamicins; Inflammation; Interleukin-1beta; Kidney Diseases; Male; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Protective Agents; Rats; Rats, Sprague-Dawley; Signal Transduction; Tetrazoles; Tumor Necrosis Factor-alpha | 2019 |